The TGR5 signaling pathway is essential in regulating intestinal GLP1 secretion in vivo, and pharmacological targeting of TGR5 may constitute a promising incretin-based strategy for the treatment of diabetes and related metabolic disorders [103]. This evidence concerns the gene GPBAR1 and Other metabolic disease.